
News and Publications
Publication Categories
7 Hills Pharma to Deliver Video Presentation At BIO Digital 2020 June 8 – 12
7 Hills Pharma’s integrin platform technology enhances immunotherapies, boosting COVID-19 vaccine efficacy and checkpoint inhibitors by improving cell adhesion for stronger immune responses. Learn more from BIO Digital 2020.
7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
7 Hills Pharma launches a COVID-19 vaccine program targeting at-risk elderly, leveraging integrin activator technology to enhance immune responses and improve vaccine effectiveness. Learn more about this breakthrough approach.
Integrin-mediated augmentation of antigenic immunity
Explore how 7HP349, a novel integrin activator, enhances immune responses in cancer therapy and vaccine efficacy. Learn about its role in boosting T cell activation, checkpoint blockade, and pathogen-specific immunity with a strong safety profile.
Potentiating immune checkpoint blockade therapeutic efficacy using a small molecule activator of integrin cell adhesion receptors
Discover how the small molecule integrin activator 7HP349 enhances immune checkpoint blockade therapy by promoting T cell infiltration into tumors. Learn about its role in boosting anti-CTLA-4 and anti-PD-L1 efficacy in melanoma and colon cancer models.
Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment
Explore the complex relationship between the immune system and cancer, focusing on integrins and cell adhesion molecules in tumor development, immune responses, and cancer immunotherapy strategies.
7 Hills Pharma Appoints Lionel D. Lewis as Chief Medical Officer
7 Hills Pharma appoints Dr. Lionel D. Lewis as Chief Medical Officer, bringing extensive immuno-oncology expertise to advance 7HP349 integrin activator for solid tumor treatment. Learn more about this leadership addition.
7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program
7 Hills Pharma forms a Scientific Advisory Board with top immuno-oncology experts to advance its integrin activator program, aiming to enhance checkpoint inhibitors and improve cancer immunotherapy effectiveness.
7 Hills Pharma Launches With $2 Million SBIR Grant in addition to $4 Million in Seed Capital to Pursue Novel Cancer Therapeutics to Promote a Productive Immune Response and Overcome Drug Resistance
7 Hills Pharma secures a $2M SBIR grant from the NIH, alongside $4M in seed funding, to develop integrin activators that enhance cancer immunotherapy and improve checkpoint inhibitor effectiveness in treating solid tumors.
Cancer vaccines: trafficking of tumor-specific T cells to tumor after therapeutic vaccination
Discover how cancer vaccines enhance tumor-specific CD8+ T cell trafficking, activation, and infiltration for effective tumor regression. Learn about next-generation immunotherapy strategies to improve cancer vaccine efficacy.
T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy
Discover how tumors evade immune responses and limit cancer immunotherapy success. Explore strategies to enhance T-cell and NK-cell infiltration, overcome tumor immune barriers, and improve treatment efficacy.
Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion
Discover THI0019, the first small molecule agonist of VLA-4 integrin, designed to enhance progenitor cell adhesion and improve stem cell therapy outcomes. Learn how integrin activation can boost cell retention, migration, and engraftment.
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Explore the link between angiogenesis and immunosuppression in cancer. Learn how tumors exploit these processes and discover emerging cancer therapies targeting both vascular growth and immune evasion.
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes
Discover how agonist anti-CD137 monoclonal antibodies enhance T cell recruitment by acting on tumor endothelial cells. Learn about their role in cancer immunotherapy and potential for improving immune infiltration in tumors.
The importance of prolonged binding to antigen-presenting cells for T cell fate decisions
Discover the crucial role of prolonged T cell interactions with antigen-presenting cells (APCs) in immune response regulation. Learn how ICAM-1 and LFA-1 signaling influence T cell activation, memory formation, and immune system efficiency.
Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory
Discover how ICAM-1 expression on dendritic cells regulates CD8+ T cell priming, immune memory formation, and cytotoxic T lymphocyte activation. Learn about the role of long-lasting DC-T cell interactions in effective immune responses.
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Explore how the Endothelin B receptor (ETBR) inhibits T cell homing, limiting tumor immunotherapy efficacy. Learn about ICAM-1’s role in immune cell infiltration and how ETBR blockade can enhance cancer treatment outcomes.
Tumor blood vessels, a difficult hurdle for infiltrating leukocytes
Explore how tumors evade immune responses by suppressing endothelial adhesion molecules, limiting leukocyte recruitment. Learn about novel strategies to enhance immune cell infiltration and improve cancer immunotherapy outcomes.
Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma
Explore how Vascular Adhesion Protein-1 (VAP-1) and ICAM-1 facilitate T cell adhesion to tumor endothelium in hepatocellular carcinoma (HCC). Learn about their role in tumor immune infiltration and potential implications for cancer immunotherapy.
Regulation of human T lymphocyte coactivation with an alpha4 integrin antagonist peptide
Discover how the cyclic hexapeptide CWLDVC (TBC 772) acts as an alpha4 integrin antagonist, effectively inhibiting human T lymphocyte coactivation and immune cell adhesion. Learn about its potential in targeted immune therapies.
Alpha 4 beta 1 (CD49d/CD29) integrin costimulation of human T cells enhances transcription factor and cytokine induction in the absence of altered sensitivity to anti-CD3 stimulation
Explore how Alpha 4 Beta 1 (CD49d/CD29) integrin enhances T cell costimulation, driving cytokine induction and transcription factor activation. Learn about its role in immune cell signaling and response modulation.